Lung Neoplasms: Tumors or cancer of the LUNG.Tetranitromethane: Corrosive oxidant, explosive; additive to diesel and rocket fuels; causes skin and lung irritation; proposed war gas. A useful reagent for studying the modification of specific amino acids, particularly tyrosine residues in proteins. Has also been used for studying carbanion formation and for detecting the presence of double bonds in organic compounds.Chloroprene: Toxic, possibly carcinogenic, monomer of neoprene, a synthetic rubber; causes damage to skin, lungs, CNS, kidneys, liver, blood cells and fetuses. Synonym: 2-chlorobutadiene.Flame Retardants: Materials applied to fabrics, bedding, furniture, plastics, etc. to retard their burning; many may leach out and cause allergies or other harm.Adenocarcinoma, Bronchiolo-Alveolar: A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)Propylene Glycols: Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations.Lung: Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.Genes, ras: Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Codon: A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE).Lung Diseases: Pathological processes involving any part of the LUNG.Lung Injury: Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Lung Transplantation: The transference of either one or both of the lungs from one human or animal to another.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Acute Lung Injury: A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).Skin Neoplasms: Tumors or cancer of the SKIN.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Lung Volume Measurements: Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.DNA, Neoplasm: DNA present in neoplastic tissue.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Liver Neoplasms: Tumors or cancer of the LIVER.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Total Lung Capacity: The volume of air contained in the lungs at the end of a maximal inspiration. It is the equivalent to each of the following sums: VITAL CAPACITY plus RESIDUAL VOLUME; INSPIRATORY CAPACITY plus FUNCTIONAL RESIDUAL CAPACITY; TIDAL VOLUME plus INSPIRATORY RESERVE VOLUME plus functional residual capacity; or tidal volume plus inspiratory reserve volume plus EXPIRATORY RESERVE VOLUME plus residual volume.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Pulmonary Alveoli: Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.Extravascular Lung Water: Water content outside of the lung vasculature. About 80% of a normal lung is made up of water, including intracellular, interstitial, and blood water. Failure to maintain the normal homeostatic fluid exchange between the vascular space and the interstitium of the lungs can result in PULMONARY EDEMA and flooding of the alveolar space.Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Neoplasms, Radiation-Induced: Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.Bronchoalveolar Lavage Fluid: Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.Nose Neoplasms: Tumors or cancer of the NOSE.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Small Cell Lung Carcinoma: A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Adenoma: A benign epithelial tumor with a glandular organization.Eye Neoplasms: Tumors or cancer of the EYE.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Neoplasms, Muscle Tissue: Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Uterine Neoplasms: Tumors or cancer of the UTERUS.Lung Abscess: Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Vascular Neoplasms: Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.Neoplasms, Adnexal and Skin Appendage: Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.Ventilator-Induced Lung Injury: Lung damage that is caused by the adverse effects of PULMONARY VENTILATOR usage. The high frequency and tidal volumes produced by a mechanical ventilator can cause alveolar disruption and PULMONARY EDEMA.Neoplasms, Complex and Mixed: Neoplasms composed of more than one type of neoplastic tissue.Sweat Gland NeoplasmsColonic Neoplasms: Tumors or cancer of the COLON.Palatal Neoplasms: Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Mandibular Neoplasms: Tumors or cancer of the MANDIBLE.Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Splenic Neoplasms: Tumors or cancer of the SPLEEN.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Heart Neoplasms: Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Respiratory Function Tests: Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Pneumonia: Infection of the lung often accompanied by inflammation.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Maxillary Neoplasms: Cancer or tumors of the MAXILLA or upper jaw.Mice, Inbred C57BLPneumonectomy: The excision of lung tissue including partial or total lung lobectomy.Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Anal Gland Neoplasms: Tumors or cancer of the anal gland.Pleural Neoplasms: Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Mediastinal Neoplasms: Tumors or cancer of the MEDIASTINUM.Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.Pulmonary Edema: Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.Neoplasms, Adipose Tissue: Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Farmer's Lung: A form of alveolitis or pneumonitis due to an acquired hypersensitivity to inhaled antigens associated with farm environment. Antigens in the farm dust are commonly from bacteria actinomycetes (SACCHAROPOLYSPORA and THERMOACTINOMYCES), fungi, and animal proteins in the soil, straw, crops, pelts, serum, and excreta.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Cell Line, Tumor: A cell line derived from cultured tumor cells.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Smoking: Inhaling and exhaling the smoke of burning TOBACCO.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Mouth Neoplasms: Tumors or cancer of the MOUTH.Carcinogens: Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.Respiratory Distress Syndrome, Adult: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.Stomach Neoplasms: Tumors or cancer of the STOMACH.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Breast Neoplasms: Tumors or cancer of the human BREAST.Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.Pulmonary Circulation: The circulation of the BLOOD through the LUNGS.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Tongue Neoplasms: Tumors or cancer of the TONGUE.Muscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)Ileal Neoplasms: Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).Carcinoma, Acinar Cell: A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Nervous System Neoplasms: Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.Spinal Cord Neoplasms: Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.Bronchi: The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.Pulmonary Emphysema: Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.Vaginal Neoplasms: Tumors or cancer of the VAGINA.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Pulmonary Surfactants: Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.Adenoma, Oxyphilic: A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.Janus Kinase 2: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.Respiratory Mucosa: The mucous membrane lining the RESPIRATORY TRACT, including the NASAL CAVITY; the LARYNX; the TRACHEA; and the BRONCHI tree. The respiratory mucosa consists of various types of epithelial cells ranging from ciliated columnar to simple squamous, mucous GOBLET CELLS, and glands containing both mucous and serous cells.Myelodysplastic-Myeloproliferative Diseases: Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.Paranasal Sinus Neoplasms: Tumors or cancer of the PARANASAL SINUSES.Pancreatectomy: Surgical removal of the pancreas. (Dorland, 28th ed)Cerebral Ventricle Neoplasms: Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.Abdominal NeoplasmsPeripheral Nervous System Neoplasms: Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.

*  Search of: lung neoplasms AND (woman OR women OR female) - Search Details - ClinicalTrials.gov

lung neoplasms: 6,088 studies Lung Cancer. Lung carcinoma. lung tumors. Carcinoma of the Lung. Cancer of the Lung. Neoplasm of ... Cancer of Lung. CARCINOMA OF LUNG. Neoplasm of the lung. pulmonary carcinoma. Pulmonary neoplasia. Tumor of lung. Tumor of the ... neoplasms: 63,279 studies Cancer. Tumor. Oncology. Malignancy. neoplastic syndrome. Neoplasia. Malignant Growth. Neoplastic ...
https://clinicaltrials.gov/ct2/results/details?term=lung neoplasms AND

*  Reduction of lung parenchyma compliance as a factor in the genesis of pleural effusion in neoplasms.

We suggest that a reduction in the compliance of the lung parenchyma, w ... 371059 - Passive expiration as a test of lung function.. 3140199 - Identifying lung overdistention during mechanical ... Lung Compliance / physiology*. Models, Biological. Pleural Effusion, Malignant / etiology*, physiopathology, radiography. ... We suggest that a reduction in the compliance of the lung parenchyma, whatever its cause (apart from bronchial obstruction), ...
biomedsearch.com/nih/Reduction-lung-parenchyma-compliance-as/11812189.html

*  "Primary lung and large airway neoplasms in children. Current imaging e" by Behrang Amini, Steven Y. Huang et al.

Primary lung and large airway neoplasms in children. Current imaging evaluation with multidetector computed tomography ... Primary lung and large airway neoplasms in children. current imaging evaluation with multidetector computed tomography. ...
hsrc.himmelfarb.gwu.edu/smhs_rad_facpubs/58/

*  NIOSHTIC-2 Publications Search - 00237879 - Dose-response associations of silica with nonmalignant respiratory disease and...

... exposure and lung cancer and nonmalignant respiratory disease (NMRD) risk among DE industry workers. The cohort consisted of ... lung neoplasms; occupational exposure; respiratory tract diseases; silicon dioxide ... Mortality from lung cancer and NMRD was significantly increased, SMRs 1.29 and 2.01, respectively. NMRD mortality increased ... Adjusting for smoking reduced the maximum RRs for NMRD and lung cancer to 4.15 and 1.67, respectively. The authors conclude ...
https://cdc.gov/niosh/nioshtic-2/00237879.html

*  Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer - Full Text View -...

Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. ... Non-small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Drug: docetaxel Drug: ... Lung Diseases. Respiratory Tract Diseases. Carcinoma, Bronchogenic. Bronchial Neoplasms. Docetaxel. Bortezomib. Antineoplastic ... Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer. This study has been ...
https://clinicaltrials.gov/ct2/show/NCT00362882

*  A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer. - Full Text View - ClinicalTrials...

Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. ... Lung Diseases. Respiratory Tract Diseases. Carcinoma, Bronchogenic. Bronchial Neoplasms. Erlotinib Hydrochloride. ... Non-Small Cell Lung Cancer Drug: Doxycline Drug: erlotinib [Tarceva] Phase 2 ... A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.. This study has been completed. ...
https://clinicaltrials.gov/ct2/show/NCT00531934

*  Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy - Full Text View -...

Bronchial Neoplasms. Lung Neoplasms. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung ... Carcinoma, Non-Small-Cell Lung. Gastrointestinal Neoplasms. Carcinoma, Bronchogenic. ... Carcinoma, Non-Small-Cell Lung Cancer of the Gastrointestinal Tract Behavioral: Standard Exercise Behavioral: Qigong Exercise ... Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy. This study has ...
https://clinicaltrials.gov/show/NCT01374100

*  Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose...

Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. ... Lung Diseases. Respiratory Tract Diseases. Carcinoma, Bronchogenic. Bronchial Neoplasms. Gemcitabine. Cisplatin. Antineoplastic ... Non-Small Cell Lung Cancer Drug: gemcitabine Drug: cisplatin Procedure: radical surgery Procedure: chemoradiotherapy Phase 2 ... in Patients With Lung Cancer With Positive Nodes. This study has been completed. ...
https://clinicaltrials.gov/ct2/show/NCT00490659

*  NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma - Full Text View - ClinicalTrials.gov

Neoplasms by Histologic Type. Neoplasms. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Lung Diseases. ... Adenocarcinoma of Lung Stage IIIB Adenocarcinoma of Lung Stage IV Drug: NOV120101 (Poziotinib) Phase 2 ... Lung Neoplasms. Carcinoma. Neoplasms, Glandular and Epithelial. ... Known preexisting interstitial lung disease (ILD). *NYHA class ... NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma. This study has been terminated. ...
https://clinicaltrials.gov/ct2/show/NCT01819428?cond="Adenocarcinoma of lung"&rank=1

*  Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung...

Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Adenocarcinoma. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by ... Adenocarcinoma of the Lung Adenosquamous Cell Lung Cancer Large Cell Lung Cancer Squamous Cell Lung Cancer Stage IIIA Non-small ... Neoplasms. Lung Diseases. Respiratory Tract Diseases. Carcinoma, Bronchogenic. Bronchial Neoplasms. Carcinoma. Neoplasms, ... Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Drug: shark cartilage extract AE-941 Other: placebo Drug: cisplatin Drug ...
https://clinicaltrials.gov/show/NCT00005838

*  Best Lung Cancer Treatment Center in Los Angeles California

Looking for the best lung cancer treatment center in Los Angeles? CyberKnife offers a non-invasive lung cancer treatment with a quick recovery time.
pasadenacyberknife.com/best-lung-cancer-treatment-centers

*  Research Shows Half of Advanced Lung Cancer Patients Receive Chemotherapy

Research that sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages is published
medindia.net/news/Research-Shows-Half-of-Advanced-Lung-Cancer-Patients-Receive-Chemotherapy-74902-1.htm

*  Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients - Full Text View - ClinicalTrials.gov

Between 10% and 25% of newly diagnosed stage IIIB/stage IV patients currently receive single agent chemotherapy regimens. A significant proportion of these patients will be elderly (70 years of age) and many oncologists would consider intravenous vinorelbine or gemcitabine to be the standard of care in this patient population. It has been demonstrated that single agent vinorelbine offers therapeutic advantages to selected NSCLC patients over best supportive care alone.. Carboplatin plus Alimta have an acceptable toxicity profile and few clinical problems so it could be acceptable its use in elderly patients.. A randomised study is being performed therefore to assess whether progression free survival, the primary efficacy endpoint for this study, achieved with Carboplatin plus Alimta is superior than achieved with gemcitabine, one of the current standards of care in elderly patients with advanced NSCLC. ...
https://clinicaltrials.gov/ct2/show/NCT00754364

*  Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) - Full Text...

cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle ...
https://clinicaltrials.gov/ct2/show/NCT00148798

*  Plus it

Lung cancer is the most common cause of cancer mortality worldwide and continues to be a major health problem, exceeding the combined mortality rates of colorectal, breast and prostate cancers. It has proven difficult to control lung cancer with conventional therapeutic and surgical approaches, and generally the prognosis is poor with an overall five-year survival rate of 10-14% in the USA. A competent approach to reduce the mortality from lung cancer is the early detection of premalignant lesions as the survival of early stage lung cancer patients is much better as compared to patients with advanced cancers. The current mainstays of lung cancer therapy are surgical resection, radiation ablation and systemic chemotherapy with considerable toxicity. However, it appears unlikely that these therapies can cause striking improvements in near future. Thus, effective approaches to the prevention of lung cancer need ...
cancerres.aacrjournals.org/content/70/8_Supplement/951

*  Brachytherapy for Lung Cancer Treatment - Lung Cancer Blog

Lung cancer treatment start with the detailed staging scans as it is very necessary to know the stage and exact location of the cancer affected area. The
https://lungcancersymptomsx.com/brachytherapy-for-lung-cancer-treatment.html

*  Lung Cancer Treatment | Life Extension

Lung cancer treatment depends on the subtype of the cancer and its stage. The initial treatment for stage I or II NSCLC is surgery, usually followed by chemotherapy and radiation.
lifeextension.com/protocols/cancer/lung-cancer/Page-07

*  Survival after resection of synchronous bilateral lung cancer

Abstract: Objective: Due to recent advances in imaging, the incidence of patients presenting with bilateral lung lesions is increasing. A single contralateral lung lesion can be an isolated metastasis or a synchronous second primary lung cancer. For the revision of the TNM in 2009, the International Association for the Study of Lung Cancer Staging Committee proposes that patients with contralateral lung nodules remain classified as M1 disease. In this retrospective study, the survival after resection of synchronous bilateral lung cancer is evaluated. Methods: From our database of bronchial carcinoma, all patients with bilateral synchronous lung lesions between 1990 and 2007 were retrieved. We analysed 57 patients in which, after functional assessment and thorough staging, the decision was taken to treat the disease with bilateral resection. All these files were retrospectively reviewed. ...
connection.ebscohost.com/c/articles/35327846/survival-after-resection-synchronous-bilateral-lung-cancer

*  Progress in Respiratory Research Series. Volume 29. Updates in Advances in Lung Cancer. | Thorax

Reasonably digestible reviews of recent clinical trials in the management of lung cancer are rare and, in general terms, this 11 chapter book is welcome. The emphasis here is on the use of chemotherapy and radiotherapy in the management of lung cancer, with eight of the 11 chapters considering these aspects, and the other three are concerned with chemoprevention, palliative medicine, and molecular biology.. Nine of the 11 authors are from the USA. The chapters take the form of a traditional review and are reasonably well set out with an average of about 50 references for each topic. The strengths of the book are the comprehensive assessment of novel drug therapies, with separate chapters for paclitaxel/carboplatin, gemcitabine, and docetaxel in non-small cell lung cancer, and a separate chapter on novel drugs for small cell lung cancer, including the topoisomerase-1 inhibitors, carboplatin, and the taxanes.. Sadly, the volume lacks an ...
thorax.bmj.com/content/53/5/438.1

*  Related conditions - Lung Cancer - Causes, Symptoms, Treatment, Diagnosis - Canoe.com

Related conditions - More men and women, usually between the ages of 70 and 79, die of lung cancer than any other cancer. The majority of lung cancers start in the bronchi, which are the airways that lead to the lungs. There are different types of lung cancer. The most common is called non-small cell lung cancer, which includes adenocarcinoma, large cell carcinoma, and squamous cell carcinoma. The other type of lung cancer is small cell carcinoma (or oat cell carcinoma).
chealth.canoe.com/channel/lung-health/related-conditions/lung-cancer

*  Dog Lung Cancer Symptoms | eHow

Dog Lung Cancer Symptoms. Lung cancer is a rare disease in dogs, but it is crippling and potentially fatal when it does occur. **Some dogs with lung tumors don't show any signs of sickness at all, but many develop visible symptoms like chronic coughing, weight loss and bodily weakness**. Take your pet to a medical professional immediately if he has...
ehow.com/facts_5472465_dog-lung-cancer-symptoms.html

*  Plus it

BCAR4 was identified as tamoxifen resistance related gene in breast cancer due to its function to activate estrogen-independent cell growth. Instead of estrogen receptor, ERBB2 and ERBB3 genes were activated by BCAR4 in tamoxifen resistant cells. Recently, the function of BCAR4 as a long non-coding RNA (lncRNA) was reported to regulate a non-canonical Hedgehog/GLI2 pathway in breast cancer. However, the association of BCAR4 and lung cancer has not been identified. Here, we describe the oncogenic effect of BCAR4 in human lung cancer. Expression pattern of BCAR4 was examined in lung cancer cell lines, primary tumor tissues, and adjacent normal tissues. BCAR4 was highly expressed in 71% of lung cancer cell lines and especially in 43% of cancer tissues of lung adenocarcinoma patients who did not harbor the activational mutations of EGFR nor KRAS. Exogenous expression of BCAR4 protein promoted cell growth of non-tumorigenic ...
cancerres.aacrjournals.org/content/77/13_Supplement/3137

*  Plus it

FUS1 is a novel tumor suppressor gene identified in the human chromosome 3p21.3 region. FUS1 gene was scarcely mutated both in lung cancer cell lines and primary lung cancers specimens, and the expression level mRNA similar to normal lung tissue. However, loss or reduction of FUS1 protein expression frequently occurs in lung cancer cell lines and primary lung cancers. It may due to haploinsufficiency and deficiency of posttranslational myristoylation which leads protein prone to rapid proteasome-dependent degradation or, alternatively, it may be resulted from translation repression by gene silencing of microRNA. FUS1 mRNA expression has been detected in numerous normal tissues such as heart, lung, skeletal muscle, kidney, brain, liver, pancreas and placenta. Herein, we examined the FUS1 mRNA expression by RT-PCR assay in 16 mesenchymal tumor cell lines and normal fibroblast cells, and in 110 malignant and 28 ...
cancerres.aacrjournals.org/content/69/9_Supplement/615

*  UC Davis scientists identify new target for lung cancer treatment

A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time. The findings will be published in the November issue of Cancer Research.
ucdmc.ucdavis.edu/publish/news/surgery/7149

*  A A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer - AdisInsight

This phase I/II trial studies the side effects and best dose of onalespib lactate when given together with erlotinib hydrochloride and to see how well they work
adisinsight.springer.com/trials/700260339

*  Network Now for the Upcoming Multi-disciplinary Thoracic Oncology: State-of-the-art and new directions

More information about the Multi-disciplinary Thoracic Oncology: State-of-the-art and new directions is listed in the event details below. Log in now or scroll down to get extensive content about the Multi-disciplinary Thoracic Oncology: State-of-the-art and new directions, including audience size, exhibitors, contact names, booth sizes, pricing information and more. And search Events In America for details on other festivals, events, tradeshows, conferences, meetings, seminars, conventions, and fairs.
eventsinamerica.com/events/multi-disciplinary-thoracic-oncology-state-of-the-art-and-new-directions/ev5369357c3ab22/

*  Synta Pharmaceuticals Announces Fast Track Designation Granted for Ganetespib in Non Small Cell Lung Adenocarcinoma

LEXINGTON, Mass.----Synta Pharmaceuticals Corp. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to the
biospace.com/News/synta-pharmaceuticals-announces-fast-track/308527/source=MoreNews

*  Gemcitabine (Gemzar®) | OncoLink

Gemcitabine is a chemotherapy medication used in the treatment of ovarian cancer, non small cell lung cancer, and pancreatic cancer.
oncolink.org/cancer-treatment/chemotherapy/oncolink-rx/gemcitabine-gemzar-r

*  Plus it

In this study, we report that in contrast to the malignant primary tumors, the spontaneous pulmonary metastases developed in PDX models can lose their metastatic potential and mesenchymal status and gain a more epithelial and differentiated status. This feature might be generalized to a group of patients with breast cancer with tumor metastases in the brain, liver, and lymph nodes (34). This phenomenon had initially been unexpected and was against the EMT dogma proposed in metastasis (42). However, more and more studies support that MET along with an epithelial state is required for colonization at the late stage of metastasis (43-45). Although there is still debate in the field, our studies indicate that metastasis is a complex procedure and the tumor cells that make it to the last step of colonization may not necessarily be very proliferative and mobile again. Similarly, an acquired luminal and nonmetastatic feature had been previously observed in certain breast cancer cell lines derived from ...
cancerres.aacrjournals.org/content/74/24/7406

*  Plus it

Although transforming growth factor ≤ (TGFβ) is anti-cancer identified, it was also known to promote tumor malignancy by enhancing the growth, epithelial to mesenchymal transition (EMT), tissue invasion and metastasis in a variety of cancer cells, including non-small cell lung cancers (NSCLCs). The aim of this study was to know the contribution of peroxisome proliferator-activated receptor ≤ (PPARδ) to TGFβ-promoted EMT and metastasis in NSCLCs. The degree of EMT, cell scattering, migration and invasion, and protein expression of PPARδ were first analyzed and compared between H460 and CH27 cells with or without TGFβ treatment (both are NSCLC cell lines). Chemical or shRNA blocking assay was also utilized to further confirm the importance of PPARδ in promoting TGFβ-induced tumor metastasis. Finally, signaling pathway(s) responsible for TGFβ/PPARδ-mediated metastasis was evaluated. The results demonstrated that TGFβ can effectively triggered the EMT, cell scattering, migration and ...
cancerres.aacrjournals.org/content/72/8_Supplement/3028

*  Identify the Common Signs & Symptoms of Lung Cancer

Treating the early signs and symptoms of lung cancer greatly increases your chances of recovering. Learn more about CyberKnife lung cancer treatment.
pasadenacyberknife.com/conditions/lung-cancer/symptoms

*  Benefit of targeted lung cancer therapy confirmed | (e) Science News

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
esciencenews.com/articles/2011/06/03/benefit.targeted.lung.cancer.therapy.confirmed

*  50% Rise in Lung Cancer Deaths Seen From Smoking - latimes

Increased cigarette smoking worldwide will result in a 50% rise in lung cancer deaths by the year 2000, according to a study released Saturday.More than 1 billion people in the world smoke
articles.latimes.com/1986-01-12/news/mn-27174_1_lung-cancer-deaths

*  Plus it

Purpose: Here, we sought to identify critical genes, whose depletion and inhibition caused differential cytotoxicity in SMARCA4-mutant non-small cell lung cancers (NSCLCs).. Background: The SWI/SNF complex is a master regulator of gene expression, affecting at least 10% of the transcriptome. Because of its crucial role in controlling cell cycle, development and differentiation, the SWI/SNF complex components function as tumor suppressor genes. Therefore, not surprisingly, the ATPases SMARCA2 and SMARCA4 are frequently down-regulated in cancers and mutations of SMARCA4 are frequently present in many cancer types including lung cancers. However, currently, no single therapeutic agent has been identified as synthetically lethal with SMARCA4 loss.. To identify SMARCA4-inactivating mutation related targetable gene products, we developed and applied a high throughput cell-based one-well/one-gene screening platform with a genome-wide synthetic library of chemically synthesized ...
cancerres.aacrjournals.org/content/76/14_Supplement/LB-318

*  Plus it

Novel cancer therapeutics target proteins with key functions in cell survival and migration, protein turnover, mitosis regulation, or angiogenesis. These targets include receptor tyrosine (Y) kinases (e.g. BCR/ABL, EGF-R, FLT-3, Her-2, PDGF-R, KDR, c-KIT, Src, VEGF-R), serine-threonine (S/T) specific kinases (e.g. Aurora A/B (ARK), B-raf), and the chaperone Hsp90. At Oncotest, a unique profiling screen for anticancer agents is routinely done, using a clonogenic assay in a panel of 48 proprietary solid tumor xenografts. The xenograft models were in general established directly from patient tumors, representing all major tumor histotypes (non-small cell lung cancer/NSCLC, pancreatic, prostate, colon, gastric, breast, ovarian and renal cancer, melanoma and sarcoma) as well as niche tumors (pleuramesothelioma, bladder and head and neck cancer). After an initial profiling screen in the 48 tumor panel, follow-up testing in defined tumor histotypes are of high value for hypothesis generation and ...
cancerres.aacrjournals.org/content/71/8_Supplement/3528

Targeted therapy of lung cancer: Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.TetranitromethaneChloropreneTris(1,3-dichloro-2-propyl)phosphateDipropylene glycolLung receptor: Lung receptors sense irritation or inflammation in the bronchi and alveoli.Codon Adaptation Index: The Codon Adaptation Index (CAI) is the most widespread technique for analyzing Codon usage bias. As opposed to other measures of codon usage bias, such as the 'effective number of codons' (Nc), which measure deviation from a uniform bias (null hypothesis), CAI measures the deviation of a given protein coding gene sequence with respect to a reference set of genes.Chronic lung diseasePemetrexedPancreatoblastomaLung allocation score: The lung allocation score (LAS) is a numerical value used by the United Network for Organ Sharing (UNOS) to assign relative priority for distributing donated lungs for transplantation within the United States. The lung allocation score takes into account various measures of a patient's health in order to direct donated organs towards the patients who would best benefit from a lung transplant.Cystic, mucinous, and serous neoplasms: Cystic, mucinous, and serous neoplasms is a group of tumors.Kidney tumour: Kidney tumours (or kidney tumors), also known as renal tumours, are tumours, or growths, on or in the kidney. These growths can be benign or malignant (cancerous).Non-specific interstitial pneumonia: Non-specific interstitial pneumonia (NSIP) is a form of idiopathic interstitial pneumonia.Adenocarcinoma of the lung: Adenocarcinoma of the lung (pulmonary adenocarcinoma) is a common histological form of lung cancer that contains certain distinct malignant tissue architectural, cytological, or molecular features, including gland and/or duct formation and/or production of significant amounts of mucus.Thyroid cancerIntraductal papillary mucinous neoplasmMyelodysplastic–myeloproliferative diseases: Myelodysplastic–myeloproliferative diseases are a category of hematological malignancies disorders created by the World Health Organization which have characteristics of both myelodysplastic and myeloproliferative conditions.ABCD rating: ABCD rating, also called the Jewett staging system or the Whitmore-Jewett staging system, is a staging system for prostate cancer that uses the letters A, B, C, and D.Metastatic liver disease: A liver metastasis is a malignant tumor in the liver that has spread from another organ affected by cancer. The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein).Sialoblastoma: A sialoblastoma is a low-grade salivary gland neoplasm that recapitulates primitive salivary gland anlage. It has previously been referred to as congenital basal cell adenoma, embryoma, or basaloid adenocarcinoma.Solution precursor plasma spray: Solution Precursor Plasma Spray (SPPS) is a thermal spray process where a feedstock solution is heated and then deposited onto a substrate. Basic properties of the process are fundamentally similar to other plasma spraying processes.Goblet cell carcinoid: The goblet cell carcinoid, abbreviated GCC and also known as crypt cell carcinoma and neuroendocrine tumour with goblet cell differentiation, is a rare biphasic gastrointestinal tract tumour that consists of a neuroendocrine component and a conventional carcinoma, histologically arising from Paneth cells.Ovarian Cancer National Alliance: The Ovarian Cancer National Alliance is an advocacy organization for women with ovarian cancer in the United States. To advance the interests of women with ovarian cancer, the organization advocates at a national level for increases in research funding for the development of an early detection test, improved health care practices, and life-saving treatment protocols.Alveolar gas equation: The partial pressure of oxygen (pO2) in the pulmonary alveoli is required to calculate both the alveolar-arterial gradient of oxygen and the amount of right-to-left cardiac shunt, which are both clinically useful quantities. However it is not practical to take a sample of gas from the alveoli in order to directly measure the partial pressure of oxygen.Pancreatic mucinous cystic neoplasm: Pancreatic mucinous cystic neoplasm, also mucinous cystic neoplasm of the pancreas and mucinous cystic tumour, is a grouping of cystic neoplasms that arise from the pancreas. They may be benign, malignant or in between.Dense artery sign: In medicine, the dense artery sign or hyperdense artery sign is a radiologic sign seen on computer tomography (CT) scans suggestive of early ischemic stroke. In earlier studies of medical imaging in patients with strokes, it was the earliest sign of ischemic stroke in a significant minority of cases.Spaceflight radiation carcinogenesisCancer biomarkers: A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer.Small-cell carcinomaDuctal carcinoma: Ductal carcinoma is a type of tumor that primarily presents in the ducts of a gland.Aggressive digital papillary adenocarcinoma: Aggressive digital papillary adenocarcinoma (also known as a digital papillary adenocarcinoma and papillary adenoma) is a cutaneous condition characterized by an aggressive malignancy involving the digit between the nailbed and the distal interphalangeal joint spaces.Thyroid adenomaIntraocular lymphoma: Intraocular lymphoma is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye secondarily from a metastasis from a non-ocular tumor or may arise within the eye primarily (primary intraocular lymphoma, PIOL).Vascular tissue neoplasmCancer/testis antigen family 45, member a5Polymorphous low-grade adenocarcinoma: Polymorphous low-grade adenocarcinoma, often abbreviated PLGA, is a rare, asymptomatic, slow-growing malignant salivary gland tumor. It is most commonly found in the palate.Bone tumorBob ChampionGlandular and epithelial neoplasm: Glandular and epithelial neoplasm is a grouping of tumors arising from the glands and epithelium.Inflammatory myofibroblastic tumourOsteolipochondroma: Osteolipochondroma (osteo, bone, lipos, fat, + chondros, cartilage, oma, tumor) is a cartilaginous tumor containing fatty and bony tissue.Lung abscessMucinous cystadenocarcinoma of the lung: Mucinous cystadenocarcinoma of the lung (MCACL) is a very rare malignant mucus-producing neoplasm arising from the uncontrolled growth of transformed epithelial cells originating in lung tissue.Combined pulmonary fibrosis and emphysema: Combined pulmonary fibrosis and emphysema describes a medical syndrome involving both pulmonary fibrosis and emphysema. The combination is most commonly found in male smokers.Hematological Cancer Research Investment and Education Act: The Hematological Cancer Research Investment and Education Act of 2001 (P.L.World Lymphoma Awareness Day: World Lymphoma Awareness Day (WLAD) is held on September 15 every year and is a day dedicated to raising awareness of lymphoma, an increasingly common form of cancer. It is a global initiative hosted by the Lymphoma Coalition (LC), a non-profit network organisation of 63 lymphoma patient groups from 44 countries around the world.Adnexal and skin appendage neoplasms: Adnexal and skin appendage neoplasms is a group of tumors.Hidradenocarcinoma: Hidradenocarcinoma (also known as malignant hidradenoma, malignant acrospiroma, clear cell eccrine carcinoma, or primary mucoepidermoid cutaneous carcinoma) is a malignant adnexal tumor of the sweat gland. It is the malignant variant of the benign hidradenoma.Oncotype DX Colon Cancer AssayLittoral cell angioma: Littoral cell angioma, abbreviated LCA, and formally known as littoral cell angioma of the spleen, is a benign tumour of the spleen that arises from the cells that line the red pulp.Papillary serous cystadenocarcinomaOld German Shepherd Dog: Old German Shepherd Dog () is a controversial predicate for the long-hair variation of the German Shepherd Dog (), which is not a separate breed recognized by the Fédération Cynologique Internationale. Nonetheless, there are efforts to establish this variety as a separate breed.PanitumumabOvarian serous cystadenoma: Ovarian serous cystadenoma, also (less precisely) known as serous cystadenoma, is a very common benign ovarian tumour.Hospital-acquired pneumonia: Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia.Anaplastic carcinoma: Anaplastic carcinoma is a general term for a malignant neoplasm arising from the uncontrolled proliferation of transformed cells of epithelial origin, or showing some epithelial characteristics, but that reveal no cytological or architectural features of associated with more differentiated tumors, such as the glandular formation or special cellular junctions that typical of adenocarcinoma and squamous cell carcinoma, respectively.Lung cancer surgery: Lung cancer surgery describes the use of surgical operations in the treatment of lung cancer. It involves the surgical excision of cancer tissue from the lung.Eprozinol

(1/26018) Human papillomavirus DNA in adenosquamous carcinoma of the lung.

AIM: To investigate the presence of human papillomavirus (HPV) DNA in adenosquamous carcinoma of the lung--which is relatively common in Okinawa but not in mainland Japan--and examine its histological features. METHODS: Of 207 cases where primary lung cancers were surgically removed between January 1995 and June 1997 in Okinawa, 23 were adenosquamous carcinoma. HPV was detected by non-isotopic in situ hybridisation (NISH) and polymerase chain reaction (PCR) amplification with primers specific for E6 and E7 regions of the HPV genome. PCR products were analysed by Southern blotting. Immunohistochemical determination of high molecular weight cytokeratin (HMC) and involucrin was also carried out. RESULTS: 18 cases were positive for HPV DNA by PCR and NISH. HPV types 6, 11, 16, and 18 were found. Seven cases were dual positive for different types of HPV. Using NISH, HPV was also found in the squamous cell components and in neighbouring enlarged adenocarcinoma cells. The HMC and involucrin were demonstrated immunohistochemically in the same areas. CONCLUSIONS: HPV DNA was found in a high proportion (78.3%) of adenosquamous carcinomas in Okinawa, a region where HPV has previously been shown to be prevalent in squamous cell carcinoma of the lung. The adenocarcinoma cells adjacent to the squamous cell carcinoma component were enlarged and positive for HPV, HMC, and involucrin. This is thought to indicate the transition from adenocarcinoma to squamous cell carcinoma.  (+info)

(2/26018) Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

(3/26018) Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer.

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

(4/26018) Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells.

Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals.  (+info)

(5/26018) Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis.

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

(6/26018) Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression.

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.  (+info)

(7/26018) Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise.

The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.  (+info)

(8/26018) Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.

Three different membrane-type matrix metalloproteinases (MT1-, MT2-, and MT3-MMPs) are known to activate in vitro the zymogen of MMP-2 (pro-MMP-2, progelatinase A), which is one of the key MMPs in invasion and metastasis of various cancers. In the present study, we have examined production and activation of pro-MMP-2, expression of MT1-, MT2-, and MT3-MMPs and their correlation with pro-MMP-2 activation, and localization of MMP-2, MT1-MMP, and MT2-MMP in human astrocytic tumors. The sandwich enzyme immunoassay demonstrates that the production levels of pro-MMP-2 in the anaplastic astrocytomas and glioblastomas are significantly higher than that in the low-grade astrocytomas (P<0.05 and P<0.01, respectively), metastatic brain tumors (P<0.05), or normal brains (P<0.01). Gelatin zymography indicates that the pro-MMP-2 activation ratio is significantly higher in the glioblastomas than in other astrocytic tumors (P<0.01), metastatic brain tumors (P<0.01), and normal brains (P<0.01). The quantitative reverse transcription polymerase chain reaction analyses demonstrate that MT1-MMP and MT2-MMP are expressed predominantly in glioblastoma tissues (17/17 and 12/17 cases, respectively), and their expression levels increase significantly as tumor grade increases. MT3-MMP is detectable in both astrocytic tumor and normal brain tissues, but the mean expression level is approximately 50-fold lower compared with that of MT1-MMP and MT2-MMP in the glioblastomas. The activation ratio of pro-MMP-2 correlates directly with the expression levels of MT1-MMP and MT2-MMP but not MT3-MMP. In situ hybridization indicates that neoplastic astrocytes express MT1-MMP and MT2-MMP in the glioblastoma tissues (5/5 cases and 5/5 cases, respectively). Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2. In situ zymography shows gelatinolytic activity in the glioblastoma tissues but not in the normal brain tissues. These results suggest that both MT1-MMP and MT2-MMP play a key role in the activation of pro-MMP-2 in the human malignant astrocytic tumors and that the gelatinolytic activity is involved in the astrocytic tumor invasion.  (+info)



Cancer


  • Dose-response associations of silica with nonmalignant respiratory disease and lung cancer mortality in the diatomaceous earth industry. (cdc.gov)
  • A study of mortality of workers in the diatomaceous-earth (DE) industry was conducted to examine possible associations between crystalline silica (14808607) exposure and lung cancer and nonmalignant respiratory disease (NMRD) risk among DE industry workers. (cdc.gov)
  • Associations between NMRD and lung cancer mortality and cumulative silica dust exposures estimated from industrial hygiene monitoring data and detailed job histories of the decedents were examined. (cdc.gov)
  • Mortality from lung cancer and NMRD was significantly increased, SMRs 1.29 and 2.01, respectively. (cdc.gov)
  • The same comparison showed a significant, but weaker trend for lung cancer, RR 2.15. (cdc.gov)
  • Adjusting for smoking reduced the maximum RRs for NMRD and lung cancer to 4.15 and 1.67, respectively. (cdc.gov)
  • A weaker dose response trend for lung cancer has been detected. (cdc.gov)
  • These associations are unlikely to reflect the effects of asbestos exposure or smoking and add further support to the view that silica dust is involved in the etiology of lung cancer. (cdc.gov)
  • This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer. (clinicaltrials.gov)
  • I. To compare the efficacy and tolerability of sequential vs concurrent docetaxel and bortezomib in patients with previously treated, progressive or recurrent, advanced non-small cell lung cancer (NSCLC). (clinicaltrials.gov)
  • Induced Rash in Patients With Non-Small Cell Lung Cancer. (clinicaltrials.gov)
  • This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with non-small cell lung cancer who have failed first-line chemotherapy for advanced disease. (clinicaltrials.gov)
  • The investigators hypothesise that Qigong therapy is better in the reduction of anxiety and depression levels and the improvement of quality of life in patients with lung and gastrointestinal (GI) cancer who are eligible for anti-cancer treatment, when compared to standard exercise training. (clinicaltrials.gov)
  • Symptoms commonly reported by lung and GI cancer patients will be measured using the Edmonton Symptom Assessment Scale (ESAS). (clinicaltrials.gov)
  • The purpose of this study is to test feasibility, toxicity and efficacy of two different adjuvant treatment schedules in Stage II-IIIa Non-small cell lung cancer patients with positive lymph nodes. (clinicaltrials.gov)
  • AE-941 may help shrink or slow the growth of non-small cell lung cancer cells. (clinicaltrials.gov)
  • It is not yet known if combination chemotherapy plus radiation therapy is more effective with or without AE-941 for non-small cell lung cancer. (clinicaltrials.gov)
  • To prove superiority of active pain management group compared to control group by the percent of pain intensity difference of outpatients with lung cancer pain. (clinicaltrials.gov)
  • Outpatients with lung cancer. (clinicaltrials.gov)
  • The patients with uncontrolled lung cancer pain - more than and equal NRS 4 pain during previous 24 hours for background pain, or more than and equal 3 times/day for breakthrough painkiller medication. (clinicaltrials.gov)
  • PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage I or stage II non-small cell lung cancer. (clinicaltrials.gov)
  • To establish the maximum tolerated dose of CyberKnife® hypofractionated stereotactic radiosurgery in patients with medically inoperable, stage I or II non-small cell lung cancer. (clinicaltrials.gov)
  • This study combines nelfinavir (NFV) with radiation therapy and chemotherapy as a treatment for non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment. (clinicaltrials.gov)
  • This is a phase 2 trial of the HIV protease inhibitor (HPI) Nelfinavir (NFV) in combination with radiotherapy and chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment. (clinicaltrials.gov)
  • Histological diagnosis of non-small cell lung cancer that is Stage III (T1-3, pN2, M0) NSCLC in whom neoadjuvant therapy is recommended. (clinicaltrials.gov)
  • Patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study. (clinicaltrials.gov)
  • It is not yet known which combination chemotherapy regimen is most effective in treating non-small cell lung cancer. (clinicaltrials.gov)
  • PURPOSE: This randomized phase II trial is comparing different combination chemotherapy regimens to see how well they work as first-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer that cannot be removed by surgery. (clinicaltrials.gov)
  • To assess treatment outcomes of adjuvant chemotherapy based on ERCC1 and RRM1 mRNA levels in patients with stage IIIB or IV non-small cell lung cancer. (clinicaltrials.gov)
  • A patient will be considered to have died from lung cancer if he or she had evidence of disease progression at any site and no direct evidence of other cause of death. (clinicaltrials.gov)
  • It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. (clinicaltrials.gov)
  • This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer. (clinicaltrials.gov)

Bronchial


  • We suggest that a reduction in the compliance of the lung parenchyma, whatever its cause (apart from bronchial obstruction), may also lead to an increase in negative pressure in the pleural cavity and may contribute, together with the other known factors, as an additional mechanism in the appearance of pleural fluid. (biomedsearch.com)

EGFR


  • The purpose of this open-label, single-arm, multi-center phase II trial is to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), as a first-line monotherapeutic agent in patients with lung adenocarcinoma harboring EGFR mutation. (clinicaltrials.gov)